MCID: FTT008
MIFTS: 39

Fatty Liver Disease, Nonalcoholic 1

Categories: Liver diseases, Metabolic diseases

Aliases & Classifications for Fatty Liver Disease, Nonalcoholic 1

MalaCards integrated aliases for Fatty Liver Disease, Nonalcoholic 1:

Name: Fatty Liver Disease, Nonalcoholic 1 57 29
Hepatic Steatosis 75 29 6
Fatty Liver Disease, Nonalcoholic, Susceptibility to, 1 57 13
Nafld1 57 75
Non-Alcoholic Fatty Liver Disease 1 75
Steatohepatitis 73
Fatty Liver 73

Characteristics:

OMIM:

57
Inheritance:
multifactorial

Miscellaneous:
genetic heterogeneity


HPO:

32
fatty liver disease, nonalcoholic 1:
Inheritance heterogeneous


Classifications:



External Ids:

OMIM 57 613282
MeSH 44 D005234
SNOMED-CT via HPO 69 197321007 442191002
UMLS 73 C2711227

Summaries for Fatty Liver Disease, Nonalcoholic 1

OMIM : 57 The accumulation of excess triglyceride in the liver, a condition known as hepatic steatosis (or fatty liver), is associated with adverse metabolic consequences including insulin resistance and dyslipidemia. Factors promoting deposition of fat in the liver include obesity, diabetes, insulin resistance, and alcohol ingestion. Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease in Western countries. In a subset of individuals hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer (summary by Romeo et al., 2008). Cohen et al. (2011) reviewed nonalcoholic fatty liver disease. (613282)

MalaCards based summary : Fatty Liver Disease, Nonalcoholic 1, also known as hepatic steatosis, is related to lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules and hypobetalipoproteinemia, familial, 1. An important gene associated with Fatty Liver Disease, Nonalcoholic 1 is PRMT7 (Protein Arginine Methyltransferase 7). The drugs Entecavir and Ezetimibe have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and heart, and related phenotype is hepatic steatosis.

UniProtKB/Swiss-Prot : 75 Non-alcoholic fatty liver disease 1: A condition characterized by accumulation of triglycerides in the liver. It is associated with adverse metabolic consequences, including insulin resistance and dyslipidemia. In a subset of individuals, hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer. NAFLD is the most common form of liver disease in Western countries.

Related Diseases for Fatty Liver Disease, Nonalcoholic 1

Diseases in the Nonalcoholic Fatty Liver Disease family:

Fatty Liver Disease, Nonalcoholic 1 Fatty Liver Disease, Nonalcoholic 2

Diseases related to Fatty Liver Disease, Nonalcoholic 1 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.1
2 hypobetalipoproteinemia, familial, 1 11.4
3 nonalcoholic fatty liver disease 10.9

Symptoms & Phenotypes for Fatty Liver Disease, Nonalcoholic 1

Symptoms via clinical synopsis from OMIM:

57
Abdomen Liver:
fatty liver (hepatic steatosis), nonalcoholic


Clinical features from OMIM:

613282

Human phenotypes related to Fatty Liver Disease, Nonalcoholic 1:

32
# Description HPO Frequency HPO Source Accession
1 hepatic steatosis 32 HP:0001397

Drugs & Therapeutics for Fatty Liver Disease, Nonalcoholic 1

Drugs for Fatty Liver Disease, Nonalcoholic 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 432)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
2
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
3
Amlodipine Approved Phase 4 88150-42-9 2162
4
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
5
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
6
Simvastatin Approved Phase 4,Not Applicable 79902-63-9 54454
7
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
8
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
9
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
10
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
11
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
12
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
13
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
14
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
15
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 23994
16
Peginterferon alfa-2a Approved, Investigational Phase 4,Not Applicable 198153-51-4 5360545
17
Ribavirin Approved Phase 4,Phase 3,Not Applicable 36791-04-5 37542
18
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
19
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7439-89-6 23925
20
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Not Applicable 122320-73-4 77999
21
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
22
Insulin Aspart Approved Phase 4 116094-23-6 16132418
23
Insulin Detemir Approved Phase 4 169148-63-4 5311023
24
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
25
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
26
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
27
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
28
Efavirenz Approved, Investigational Phase 4,Not Applicable 154598-52-4 64139
29
Gliclazide Approved Phase 4 21187-98-4 3475
30
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
31
Tamoxifen Approved Phase 4 10540-29-1 2733526
32
Rifampicin Approved Phase 4,Phase 1 13292-46-1 5458213 5381226
33
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
34
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
35
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
36
Cortisone acetate Approved, Investigational Phase 4 1950-04-4, 50-04-4 5745
37
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
38
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754
39
Racepinephrine Approved Phase 4,Phase 2 329-65-7 838
40
Empagliflozin Approved Phase 4,Phase 3,Not Applicable 864070-44-0
41
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 80621-81-4 6436173
42
Glimepiride Approved Phase 4 93479-97-1 3476
43
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
44
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
45
Saxagliptin Approved Phase 4 361442-04-8 11243969
46
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
47
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-02-9 14985
48
Choline Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 62-49-7 305
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-30-3 6037
50
Pyridoxal Approved, Nutraceutical Phase 4,Phase 3,Phase 2 66-72-8 1050

Interventional clinical trials:

(show top 50) (show all 922)
# Name Status NCT ID Phase Drugs
1 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
2 Complex Imaging Assessment of Steatosis Unknown status NCT02669641 Phase 4
3 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
6 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
7 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
8 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
9 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
10 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
11 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
12 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
13 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
14 Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Unknown status NCT02652884 Phase 4 phosphate and betamethasone acetate, 2 mL.;saline 0.9% NaCl
15 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4 Exenatide
16 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
17 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
18 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
19 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
20 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
21 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
22 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
23 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
24 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
25 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
26 Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
27 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
28 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
29 Liver Safety Under Upfront Arimidex vs Tamoxifen Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
30 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
31 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
32 The Effects of PXR Activation on Hepatic Fat Content Completed NCT02329405 Phase 4 Rifampicin;Placebo
33 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
34 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4 Triptorelin
35 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
36 Use of Metformin in Treatment of Childhood Obesity Completed NCT02274948 Phase 4 Metformin;Placebo
37 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
38 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
39 Lactate Metabolism Study in HIV Infected Persons Completed NCT00202228 Phase 4 cofactor supplementation (thiamine, riboflavin, L-carnitine)
40 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
41 A Study of the Effects of Exercise Intensity on Insulin Sensitivity in Overweight Youth Completed NCT00755547 Phase 4
42 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent Completed NCT02660047 Phase 4 Liraglutide;Liraglutide - Placebo
43 Adding Liraglutide to High Dose Insulin: Breaking the Cycle Completed NCT01505673 Phase 4 Liraglutide;Saline
44 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Completed NCT02277587 Phase 4 Plenadren;Conventional glucocorticoid therapy
45 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
46 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4 Ribavirin;Peginterferon alfa-2a;Ribavirin;Peginterferon alfa-2a
47 SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies Completed NCT01744236 Phase 4 Liraglutide;Sitagliptin;Exenatide;Liraglutide placebo;Sitagliptin placebo;Exenatide placebo;L-NMMA
48 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Recruiting NCT02303730 Phase 4 Exenatide;insulin glargine
49 SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
50 Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus. Recruiting NCT03007329 Phase 4 Exenatide;Exenatide matching Placebo;Dapagliflozin

Search NIH Clinical Center for Fatty Liver Disease, Nonalcoholic 1

Genetic Tests for Fatty Liver Disease, Nonalcoholic 1

Genetic tests related to Fatty Liver Disease, Nonalcoholic 1:

# Genetic test Affiliating Genes
1 Fatty Liver Disease, Nonalcoholic 1 29
2 Hepatic Steatosis 29

Anatomical Context for Fatty Liver Disease, Nonalcoholic 1

MalaCards organs/tissues related to Fatty Liver Disease, Nonalcoholic 1:

41
Liver, Testes, Heart, Endothelial, Kidney, Brain, Bone

Publications for Fatty Liver Disease, Nonalcoholic 1

Articles related to Fatty Liver Disease, Nonalcoholic 1:

(show top 50) (show all 320)
# Title Authors Year
1
Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver. ( 29719598 )
2018
2
Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. ( 29946793 )
2018
3
Choline Supplementation Prevents a Hallmark Disturbance of Kwashiorkor in Weanling Mice Fed a Maize Vegetable Diet: Hepatic Steatosis of Undernutrition. ( 29786674 )
2018
4
Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. ( 29974410 )
2018
5
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model. ( 29975946 )
2018
6
Dihydrocapsiate supplementation prevented high-fat diet-induced adiposity, hepatic steatosis, glucose intolerance, and gut morphological alterations in mice. ( 29673543 )
2018
7
Epigenetic programming at the Mogat1 locus may link neonatal overnutrition with long-term hepatic steatosis and insulin resistance. ( 29812971 )
2018
8
Physical activity and Mediterranean diet based on olive tree phenolic compounds from two different geographical areas have protective effects on early osteoarthritis, muscle atrophy and hepatic steatosis. ( 29450729 )
2018
9
Human hepatic lipase overexpression in mice induces hepatic steatosis and obesity through promoting hepatic lipogenesis and white adipose tissue lipolysis and fatty acid uptake. ( 29244870 )
2017
10
USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity. ( 28718215 )
2017
11
Omega-3 PUFA ameliorates hyperhomocysteinemia-induced hepatic steatosis in mice by inhibiting hepatic ceramide synthesis. ( 28933423 )
2017
12
ANGPTL8 (Betatrophin) is Expressed in Visceral Adipose Tissue and Relates to Human Hepatic Steatosis in Two Independent Clinical Collectives. ( 28351093 )
2017
13
Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. ( 28797039 )
2017
14
The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C. ( 29258449 )
2017
15
Hepatic steatosis in participants in a program of low-dose CT screening for lung cancer. ( 28712697 )
2017
16
Shaofu Zhuyu decoction ameliorates obesity-mediated hepatic steatosis and systemic inflammation by regulating metabolic pathways. ( 28570676 )
2017
17
Computerized Tomography Based Diagnosis of Visceral Obesity and Hepatic Steatosis is Associated with Low Urine pH. ( 28587918 )
2017
18
Angiogenic factor with G patch and FHA domains 1 (Aggf1) promotes hepatic steatosis in mice. ( 27865839 )
2017
19
Hepatic Steatosis Accompanies Pulmonary Alveolar Proteinosis. ( 28489415 )
2017
20
Inverse Relationship between Hepatic Steatosis and Alanine Aminotransferase with Sex Hormone-Binding Globulin in Men. ( 28540984 )
2017
21
Biochemical mechanism underlying hypertriglyceridemia and hepatic steatosis/hepatomegaly induced by acute schisandrin B treatment in mice. ( 28086886 )
2017
22
Hepatic Diacylglycerol-Associated Protein Kinase CI/ Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans. ( 28591572 )
2017
23
Dietary sphingomyelin attenuates hepatic steatosis and adipose tissue inflammation in high-fat-diet-induced obese mice. ( 27855315 )
2017
24
Genetic variation in the microsomal triglyceride transfer protein (-493G/T) is associated with hepatic steatosis in patients infected with hepatitis C virus. ( 28356060 )
2017
25
Activation of intestinal hypoxia-inducible factor 2I+ during obesity contributes to hepatic steatosis. ( 29035368 )
2017
26
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. ( 28768177 )
2017
27
Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis. ( 28365312 )
2017
28
Corrigendum: Phytosterol esters attenuate hepatic steatosis in rats with non-alcoholic fatty liver disease rats fed a high-fat diet. ( 28836578 )
2017
29
Human leucine zipper protein promotes hepatic steatosis via induction of apolipoprotein A-IV. ( 28246167 )
2017
30
Protective effects of gomisin N against hepatic steatosis through AMPK activation. ( 27914812 )
2017
31
Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis. ( 28449094 )
2017
32
The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance. ( 28508477 )
2017
33
<i>PNPLA3</i> rs1010023 Predisposes Chronic Hepatitis B to Hepatic Steatosis but Improves Insulin Resistance and Glucose Metabolism. ( 28695131 )
2017
34
Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. ( 28859855 )
2017
35
Role of glycoprotein 78 and cidec in hepatic steatosis. ( 28656280 )
2017
36
Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. ( 29107284 )
2017
37
Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein. ( 26637457 )
2016
38
Glucagon regulates hepatic lipid metabolism via cAMP and Insig-2 signaling: implication for the pathogenesis of hypertriglyceridemia and hepatic steatosis. ( 27582413 )
2016
39
Hyperhomocysteinemia Activates the Aryl Hydrocarbon Receptor-CD36 Pathway to Promote Hepatic Steatosis in Mice. ( 26928949 )
2016
40
Transmembrane-6 superfamily member 2 (TM6SF2) E167K variant increases susceptibility to hepatic steatosis in obese children. ( 26520056 )
2016
41
PNPLA3 rs738409 Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis. ( 26419236 )
2016
42
Long noncoding RNA MALAT1 promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP-1c protein stability. ( 26935028 )
2016
43
E2F1 mediates sustained lipogenesis and contributes to hepatic steatosis. ( 26619117 )
2016
44
Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis activates Akt signaling to ameliorate hepatic steatosis. ( 26883384 )
2016
45
PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes. ( 26355465 )
2016
46
Hepatic ATF6 Increases Fatty Acid Oxidation to Attenuate Hepatic Steatosis in Mice Through Peroxisome Proliferator-Activated Receptor I+. ( 27207533 )
2016
47
Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis. ( 26860405 )
2016
48
Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity. ( 27660157 )
2016
49
N-Acetyl-L-Cysteine inhibits the development of glucose intolerance and hepatic steatosis in diabetes-prone mice. ( 27725855 )
2016
50
Soy isoflavones (Glycine max) ameliorate hypertriglyceridemia and hepatic steatosis in high fat-fed ovariectomized Wistar rats (an experimental model of postmenopausal obesity). ( 27723468 )
2016

Variations for Fatty Liver Disease, Nonalcoholic 1

ClinVar genetic disease variations for Fatty Liver Disease, Nonalcoholic 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 OPA1 NM_015560.2(OPA1): c.113_130del18 (p.Arg38_Ser43del) deletion Conflicting interpretations of pathogenicity rs863224140 GRCh38 Chromosome 3, 193614803: 193614820
2 OPA1 NM_015560.2(OPA1): c.113_130del18 (p.Arg38_Ser43del) deletion Conflicting interpretations of pathogenicity rs863224140 GRCh37 Chromosome 3, 193332592: 193332609
3 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh37 Chromosome MT, 3275: 3275
4 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh38 Chromosome MT, 3275: 3275
5 PRMT7 NM_001290018.1(PRMT7): c.322G> T (p.Glu108Ter) single nucleotide variant Pathogenic rs1014959895 GRCh37 Chromosome 16, 68363008: 68363008
6 PRMT7 NM_001290018.1(PRMT7): c.322G> T (p.Glu108Ter) single nucleotide variant Pathogenic rs1014959895 GRCh38 Chromosome 16, 68329105: 68329105
7 PRMT7 NM_001290018.1(PRMT7): c.1713C> A (p.Cys571Ter) single nucleotide variant Pathogenic GRCh37 Chromosome 16, 68389688: 68389688
8 PRMT7 NM_001290018.1(PRMT7): c.1713C> A (p.Cys571Ter) single nucleotide variant Pathogenic GRCh38 Chromosome 16, 68355785: 68355785

Expression for Fatty Liver Disease, Nonalcoholic 1

Search GEO for disease gene expression data for Fatty Liver Disease, Nonalcoholic 1.

Pathways for Fatty Liver Disease, Nonalcoholic 1

GO Terms for Fatty Liver Disease, Nonalcoholic 1

Sources for Fatty Liver Disease, Nonalcoholic 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....